Physician profile
Thomas Lundberg
NPI 1750347233
$6,503.26
in general payments reported to CMS, 2019-2025
29 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $1,006 · 2021: $1,148 · 2022: $883 · 2023: $600 · 2024: $545 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,603.14 | 2019-2022 | |
| Pfizer INC. | $663.91 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $547.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Antares Pharma, INC. | $511.79 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $445.74 | 2023-2025 | Gemtesa |
| Amgen INC. | $372.57 | 2019-2021 | |
| Astellas Pharma US INC | $279.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $265.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.09 | 2019-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $225.11 | 2022 | |
| Lilly USA, LLC | $177.16 | 2019-2022 | |
| Novo Nordisk INC | $163.18 | 2019-2020 | |
| Abbvie INC. | $135.58 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $133.29 | 2019 | |
| Halozyme INC | $101.46 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $76.34 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.18 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $62.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $61.24 | 2019 | |
| Ironshore Pharmaceuticals INC. | $57.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $56.59 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.03 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.70 | 2019-2020 | |
| Metuchen Pharmaceuticals | $29.02 | 2019 | |
| Abbott Laboratories | $24.19 | 2022 | |
| Bausch Health US, LLC | $24.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.16 | 2020 | |
| Circassia INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lundberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.